Treatment-Related Morbidity in Prostate Cancer: A Comparison of 3-Dimensional Conformal Radiation Therapy With and Without Image Guidance Using Implanted Fiducial Markers

被引:47
|
作者
Singh, Jasmeet [1 ]
Greer, Peter B. [2 ]
White, Martin A. [3 ]
Parker, Joel [1 ]
Patterson, Jackie [1 ]
Tang, Colin I. [1 ,3 ]
Capp, Anne [1 ,3 ]
Wratten, Christopher [1 ,3 ]
Denham, James W. [1 ,3 ]
机构
[1] Univ Newcastle, Calvary Mater Newcastle, Newcastle, NSW 2300, Australia
[2] Univ Newcastle, Sch Phys & Math Sci, Newcastle, NSW 2300, Australia
[3] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia
关键词
NEOADJUVANT ANDROGEN DEPRIVATION; DOSE-VOLUME CONSTRAINTS; 68; GY; RADIOTHERAPY; TRIAL; ESCALATION; TOXICITY; 3D-CRT;
D O I
10.1016/j.ijrobp.2012.07.2376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To estimate the prevalence of rectal and urinary dysfunctional symptoms using image guided radiation therapy (IGRT) with fiducials and magnetic resonance planning for prostate cancer. Methods and Materials: During the implementation stages of IGRT between September 2008 and March 2010, 367 consecutive patients were treated with prostatic irradiation using 3-dimensional conformal radiation therapy with and without IGRT (non-IGRT). In November 2010, these men were asked to report their bowel and bladder symptoms using a postal questionnaire. The proportions of patients with moderate to severe symptoms in these groups were compared using logistic regression models adjusted for tumor and treatment characteristic variables. Results: Of the 282 respondents, the 154 selected for IGRT had higher stage tumors, received higher prescribed doses, and had larger volumes of rectum receiving high dosage than did the 128 selected for non-IGRT. The follow-up duration was 8 to 26 months. Compared with the non-IGRT group, improvement was noted in all dysfunctional rectal symptoms using IGRT. In multivariable analyses, IGRT improved rectal pain (odds ratio [OR] 0.07 [0.009-0.7], P = .02), urgency (OR 0.27 [0.11-0.63], P = <.01), diarrhea (OR 0.009 [0.02-0.35], P<.01), and change in bowel habits (OR 0.18 [0.06-0.52], P<.010). No correlation was observed between rectal symptom levels and dose-volume histogram data. Urinary dysfunctional symptoms were similar in both treatment groups. Conclusions: In comparison with men selected for non-IGRT, a significant reduction of bowel dysfunctional symptoms was confirmed in men selected for IGRT, even though they had larger volumes of rectum treated to higher doses. (C) 2013 Elsevier Inc.
引用
收藏
页码:1018 / 1023
页数:6
相关论文
共 50 条
  • [11] Geometric discrepancy of image-guided radiation therapy in patients with prostate cancer without implanted fiducial markers using a commercial pseudo-CT generation method
    Kan, Hirohito
    Eguchi, Yuta
    Tsuchiya, Takahiro
    Kondo, Takuto
    Kitagawa, Yuto
    Mekata, Yuji
    Fukuma, Hiroshi
    Yoshida, Ryoya
    Kasai, Harumasa
    Kunitomo, Hiroshi
    Hirose, Yasujiro
    Shibamoto, Yuta
    PHYSICS IN MEDICINE AND BIOLOGY, 2019, 64 (06):
  • [12] Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy
    Valicenti, RK
    Bissonette, EA
    Chen, C
    Theodorescu, D
    JOURNAL OF UROLOGY, 2002, 168 (06): : 2499 - 2504
  • [13] National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer
    Sujenthiran, Arunan
    Nossiter, Julie
    Charman, Susan C.
    Parry, Matthew
    Dasgupta, Prokar
    van der Meulen, Jan
    Cathcart, Paul J.
    Clarke, Noel W.
    Payne, Heather
    Aggarwal, Ajay
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (05): : 1253 - 1260
  • [14] Economical Evaluation of Prostate Cancer Treatment Using Intensity-Modulated Radiation Therapy, 3-Dimensional Conformal Radiation Therapy and Radical Prostatectomy: A Systematic Review
    Adel, Amin
    Rezapour, Aziz
    Aboutorabi, Ali
    Kermani, Ali Taghizadeh
    Ghorbani, Hamidreza
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 39 : 57 - 65
  • [15] The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy
    Horwitz, EM
    Hanlon, AL
    Pinover, WH
    Hanks, GE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03): : 519 - 523
  • [16] Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques
    Tonetto, Fabrizio
    Magli, Alessandro
    Moretti, Eugenia
    Guerini, Andrea Emanuele
    Tullio, Annarita
    Reverberi, Chiara
    Ceschia, Tino
    Spiazzi, Luigi
    Titone, Francesca
    Prisco, Agnese
    Signor, Marco Andrea
    Buglione, Michela
    De Giorgi, Gioacchino
    Trovo, Marco
    Triggiani, Luca
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [17] Comparison of acute toxicities when utilizing image guidance for prostate cancer external beam radiation - Ultrasound vs. fiducial markers
    Hasan, I. M.
    Reddy, C.
    Mahadevan, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S539 - S539
  • [18] Reduction of planning target volume margins for prostate cancer radiotherapy on helical tomotherapy using implanted fiducial markers and daily image-guidance
    Drozdz, S.
    Schwedas, M.
    Wendt, T. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 64 - 64
  • [19] Prostate cancer:: Precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers
    Huisman, HJ
    Fütterer, JJ
    van Lin, ENJT
    Welmers, A
    Scheenen, TWJ
    van Dalen, JA
    Visser, AG
    Witjes, JA
    Barentsz, JO
    RADIOLOGY, 2005, 236 (01) : 311 - 317
  • [20] CT-MR image integration for image-guided IMRT treatment planning of localised prostate cancer using implanted fiducial markers
    Hoffmann, AL
    van Lin, ENJT
    van der Vight, LP
    van Dalen, JA
    Huisman, HJ
    Futterer, JJ
    Barentsz, JO
    Witjes, JA
    Visser, AG
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S156 - S156